Stadiul cunoaşterii.... - Gr.T. Popa

Corelaţii clinice,imunohistochimice şi morfopatologice în unele tumori de ovar
Coordonator ştiinţific:Prof.Dr.Zenovia Florentina Pricop
__________________________________________________Doctorand:Ioana Buda
38. Daponte A, Kostopoulou E, Kollia P, Papamichali R, Vanakara P, Hadjichristodoulou C. L1 (CAM) (CD171) in
ovarian serous neoplasms. Eur J Gynaecol Oncol. 2008;29(1):26-30.
39. De Nictolis M., Montironi R., Tommasoni S., Pissani E., Fabris E., Benign, LMPand well-differentited
malignant intestinal mucinous tumors of the ovary, Int J Gynecol Pathol 1994; 13: 10-21
40. Deen S, Thomson AM, Al-Nafussi A. Histopathological challenges in assessing LMPovarian tumours. Current
Diagnostic Pathology 2006; 12(5): 325-346.
41. Dembo AJ, Davy M, Stenwig AE, et al.: Prognostic factors in patients with stage I epithelial ovarian cancer.
Obstet Gynecol 75 (2): 263-73, 1990.
42. DePriest PD, Shenson D, Fried A, et al. A morphology index based on monographic findings in ovarian cancer.
Gynecol Oncol 1993;5l2:7-11.
43. Diamandis, E. P., Okui, A., Mitsui, S., Luo, L. Y., Soosaipillai, A., Grass, L. et al. (2002). Human kallikrein 11:
A new biomarker of prostate and ovarian carcinoma. Cancer Res. 62(1), 295–300.
44. Eagle K, Ledermann JA. Tumor Markers in Ovarian Malignancies. Oncologist. 1997;2(5):324-329.
45. East N, Alobaid A, Goffin F, Ouallouche K, Gauthier P. Granulosa cell tumour: a recurrence 40 years after
initial diagnosis. J Obstet Gynaecol Can. Apr 2005;27(4):363-4.
46. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in
patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 69(2): 103-8, 1998.
47. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol
1999;237:1–30.
48. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Freidman E, Foulkes
WD, Kim-Sing C,Wagner T, Tung N, Couch F, Stoppa-Lvonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-
Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA; HEReditary Ovarian Cancer
Clinical Study Group. JAMA. 296(2): 185-92, 2006.
49. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.
50. Fontanelli R, Stefanon B, Raspagliesi F, et al. Adult granulosa cell tumor of the ovary: a clinico pathologic
study of 35 cases. Tumori 1998;84:60–4.
51. Fox H, Agrawal K, Langley FA. A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with
special reference to the factors influencing prognosis. Cancer 1975;35:231–41.
52. Fox H. Pathologic prognostic factors in early stage adult-type granulosa cell tumors of the ovary. Int J Gynecol
Cancer 2003;13:1–4.
53. Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F et al. Pooled analysis of three European
case-control studies of epithelial ovarian cancer: II. Age at menarche and menopause. Int J Cancer. 49:57-60,
1991.
54. Gershenson D.M., Baker V.V., Price J.E., Hung M.C., Silva E.G., Molecular profile of advanced-stage
transitional cell carcinoma of the ovary.Am. J. Obstet Ginecol, 1997, 177-180
55. Gershenson D.M., Silva E.G., Mitcheli M.F., Atkison E.N., Wharton J.T., Transitional cell carcinoma of the
ovary. Am. J. Obst Gynecol, 1993, 168:1178-1187
56. Gershenson DM, Hartmann LC, Young RH. Ovarian Sex Cord-Stromal Tumors. In: Hoskins WJ et al, eds.
Principles and Practice of Gynecologic Oncology. 4th ed. Baltimore, Md: Lippincott Williams & Wilkins.
2005;1011-34.
78